{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:21:58Z","timestamp":1787595718209,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12325-020-01373-3","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T17:04:37Z","timestamp":1590599077000},"page":"3485-3499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Benefits of Tiotropium\/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO\u00ae and OTEMTO\u00ae Studies"],"prefix":"10.1007","volume":"37","author":[{"given":"Roland","family":"Buhl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"de la Hoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary T.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"4","key":"1373_CR1","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1378\/chest.14-2311","volume":"148","author":"ES Ford","year":"2015","unstructured":"Ford ES. Trends in mortality from COPD among adults in the United States. Chest. 2015;148(4):962\u201370.","journal-title":"Chest"},{"issue":"1","key":"1373_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41533-016-0002-x","volume":"27","author":"GT Ferguson","year":"2017","unstructured":"Ferguson GT, Karpel J, Bennett N, et al. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017;27(1):7.","journal-title":"NPJ Prim Care Respir Med."},{"key":"1373_CR3","volume-title":"Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach","author":"J Bousquet","year":"2007","unstructured":"Bousquet J, Khaltaev N. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Geneva: World Health Organization; 2007."},{"issue":"9859","key":"1373_CR4","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095\u2013128.","journal-title":"Lancet"},{"issue":"147","key":"1373_CR5","doi-asserted-by":"publisher","first-page":"170103","DOI":"10.1183\/16000617.0103-2017","volume":"27","author":"C Viniol","year":"2018","unstructured":"Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27(147):170103.","journal-title":"Eur Respir Rev"},{"key":"1373_CR6","unstructured":"World Health Organization. The top 10 causes of death. 2018. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Accessed 7 Nov 2019."},{"issue":"2","key":"1373_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1183\/09031936.02.00269802","volume":"19","author":"R Casaburi","year":"2002","unstructured":"Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217\u201324.","journal-title":"Eur Respir J"},{"key":"1373_CR8","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease\u20142020 report. 2019. https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/11\/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 7 Nov 2019."},{"key":"1373_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3389\/fphar.2019.00390","volume":"10","author":"M Malerba","year":"2019","unstructured":"Malerba M, Foci V, Patrucco F, et al. Single inhaler LABA\/LAMA for COPD. Front Pharmacol. 2019;10:390.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1373_CR10","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969\u201379.","journal-title":"Eur Respir J"},{"key":"1373_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/COPD.S62750","volume":"9","author":"D Price","year":"2014","unstructured":"Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chronic Obstr Pulm Dis. 2014;9:889\u2013904.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"1373_CR12","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. COPD diagnosis, management and prevention\u20142019 strategy. 2018. https:\/\/www.guidelines.co.uk\/respiratory\/gold-copd-2019-strategy\/454454.article. Accessed 7 Nov 2019."},{"issue":"1","key":"1373_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4046\/trd.2017.0098","volume":"81","author":"DMG Halpin","year":"2018","unstructured":"Halpin DMG. The role of tiotropium\u2009+\u2009olodaterol dual bronchodilator therapy in the management of chronic obstructive pulmonary disease. Tuberculosis Respir Dis. 2018;81(1):13\u20138.","journal-title":"Tuberculosis Respir Dis"},{"key":"1373_CR14","doi-asserted-by":"crossref","unstructured":"Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56\u2013e69.","DOI":"10.1164\/rccm.202003-0625ST"},{"key":"1373_CR15","unstructured":"National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16\u00a0s: diagnosis and management. 2019. https:\/\/www.nice.org.uk\/guidance\/ng115\/chapter\/Recommendations#ftn.footnote_3. Accessed 9 April 2020."},{"issue":"6","key":"1373_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1183\/09031936.04.00116004","volume":"23","author":"DE O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832\u201340.","journal-title":"Eur Respir J"},{"key":"1373_CR17","unstructured":"Boehringer Ingelheim Limited. Spiolto Respimat 2.5 microgram\/2.5 microgram, inhalation solution\u2014summary of product characteristics. 2017. https:\/\/www.medicines.org.uk\/emc\/medicine\/30495. Accessed 6 Nov 2019."},{"key":"1373_CR18","unstructured":"Boehringer Ingelheim. New advance in COPD maintenance treatment, Spiolto\u00ae\u00a0Respimat\u00ae, approved in first European countries [press release]. 2015.\u00a0https:\/\/www.boehringer-ingelheim.com\/press-release\/new-advance-copd-maintenance-treatment-spiolto-respimat-approved-first-european. Accessed 31 Oct 2019."},{"issue":"11","key":"1373_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.14740\/jocmr2305w","volume":"7","author":"A Alvarado-Gonzalez","year":"2015","unstructured":"Alvarado-Gonzalez A, Arce I. Tiotropium bromide in chronic obstructive pulmonary disease and bronchial asthma. J Clin Med Res. 2015;7(11):831\u20139.","journal-title":"J Clin Med Res"},{"issue":"5","key":"1373_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1586\/17512433.2015.1075389","volume":"8","author":"M Cazzola","year":"2015","unstructured":"Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol\u2009+\u2009tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015;8(5):529\u201339.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1373_CR21","unstructured":"Boehringer Ingelheim. FDA approves Stiolto\u00ae Respimat\u00ae supplemental New Drug Application (sNDA) to add data on COPD exacerbation reduction. 2018. https:\/\/www.boehringer-ingelheim.us\/press-release\/fda-approves-stiolto-respimat-supplemental-new-drug-application-snda-add-data-copd. Accessed 31 Oct 2019."},{"issue":"10","key":"1373_CR22","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium\u2009+\u2009olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312\u20139.","journal-title":"Respir Med"},{"key":"1373_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/COPD.S51592","volume":"9","author":"W Vincken","year":"2014","unstructured":"Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chronic Obstr Pulm Dis. 2014;9:215\u201328.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"2","key":"1373_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","volume":"21","author":"TJ Witek Jr","year":"2003","unstructured":"Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267\u201372.","journal-title":"Eur Respir J"},{"issue":"3","key":"1373_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199\u2013209.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1373_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","volume":"189","author":"PW Jones","year":"2014","unstructured":"Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"1373_CR27","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2147\/COPD.S138554","volume":"12","author":"M Thomas","year":"2017","unstructured":"Thomas M, Halpin DM, Miravitlles M. When is dual bronchodilation indicated in COPD? Int J Chronic Obstr Pulm Dis. 2017;12:2291\u2013305.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"2","key":"1373_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1183\/09031936.00024608","volume":"33","author":"H Watz","year":"2009","unstructured":"Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33(2):262\u201372.","journal-title":"Eur Respir J"},{"key":"1373_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1465-9921-12-33","volume":"12","author":"SN Vorrink","year":"2011","unstructured":"Vorrink SN, Kort HS, Troosters T, Lammers JW. Level of daily physical activity in individuals with COPD compared with healthy controls. Respir Res. 2011;12:33.","journal-title":"Respir Res."},{"key":"1373_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2147\/COPD.S49392","volume":"8","author":"T van der Molen","year":"2013","unstructured":"van der Molen T, Miravitlles M, Kocks JW. COPD management: role of symptom assessment in routine clinical practice. Int J Chronic Obstr Pulm Dis. 2013;8:461\u201371.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"9","key":"1373_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","volume":"67","author":"DA Mahler","year":"2012","unstructured":"Mahler DA, D\u2019Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67(9):781\u20138.","journal-title":"Thorax"},{"issue":"1","key":"1373_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41533-018-0099-1","volume":"28","author":"MK Han","year":"2018","unstructured":"Han MK, Ray R, Foo J, Morel C, Hahn B. Systematic literature review and meta-analysis of US-approved LAMA\/LABA therapies versus tiotropium in moderate-to-severe COPD. NPJ Prim Care Respir Med. 2018;28(1):32.","journal-title":"NPJ Prim Care Respir Med"},{"key":"1373_CR33","doi-asserted-by":"crossref","unstructured":"Muro S, Yoshisue H, Kostikas K, Olsson P, Gupta P, Wedzicha JA. Indacaterol\/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-na\u00efve COPD patients: a pooled analysis. Respirology. 2020;25(4):393\u2013400.","DOI":"10.1111\/resp.13651"},{"issue":"12","key":"1373_CR34","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","volume":"33","author":"MR Maleki-Yazdi","year":"2017","unstructured":"Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017;33(12):2188\u201399.","journal-title":"Adv Ther"},{"key":"1373_CR35","first-page":"A3317","volume":"199","author":"LH Bjermer","year":"2019","unstructured":"Bjermer LH, Kerwin E, Maltais F, et al. Comparative efficacy and safety of umeclidinium\/vilanterol, umeclidinium and salmeterol in symptomatic maintenance-na\u00efve and maintenance-treated chronic obstructive pulmonary disease: a pre-specified secondary analysis of the EMAX trial. Am J Respir Crit Care Med. 2019;199:A3317.","journal-title":"Am J Respir Crit Care Med"},{"key":"1373_CR36","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.2147\/COPD.S217710","volume":"14","author":"D Singh","year":"2019","unstructured":"Singh D, D\u2019Urzo AD, Donohue JF, et al. An evaluation of single and dual long-acting bronchodilator therapy as effective interventions in maintenance therapy-na\u00efve patients with COPD. Int J Chronic Obstr Pulm Dis. 2019;14:2835\u201348.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"1373_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.rmed.2016.01.001","volume":"112","author":"JF Donohue","year":"2016","unstructured":"Donohue JF, Singh D, Munzu C, Kilbride S, Church A. Magnitude of umeclidinium\/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials. Respir Med. 2016;112:65\u201374.","journal-title":"Respir Med"},{"key":"1373_CR38","doi-asserted-by":"crossref","unstructured":"Lopez-Campos JL, Carrasco Hernandez L, Munoz X, Bustamante V, Barreiro E. Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. Respirology. 2018;23(9):818\u201327.","DOI":"10.1111\/resp.13341"},{"key":"1373_CR39","doi-asserted-by":"publisher","first-page":"101841","DOI":"10.1016\/j.pupt.2019.101841","volume":"59","author":"P Rogliani","year":"2019","unstructured":"Rogliani P, Matera MG, Ritondo BL, et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019;59:101841.","journal-title":"Pulm Pharmacol Ther"},{"key":"1373_CR40","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.2147\/COPD.S146338","volume":"12","author":"P Rogliani","year":"2017","unstructured":"Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chronic Obstr Pulm Dis. 2017;12:3469\u201385.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"5","key":"1373_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","volume":"6","author":"PMA Calverley","year":"2018","unstructured":"Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Resp Med. 2018;6(5):337\u201344.","journal-title":"Lancet Resp Med"},{"key":"1373_CR42","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.2147\/COPD.S92840","volume":"11","author":"E Derom","year":"2016","unstructured":"Derom E, Brusselle GG, Joos GF. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD. Int J Chronic Obstr Pulm Dis. 2016;11:3163\u201377.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"1373_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pupt.2015.04.002","volume":"32","author":"KM Beeh","year":"2015","unstructured":"Beeh KM, Westerman J, Kirsten AM, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53\u20139.","journal-title":"Pulm Pharmacol Ther"},{"key":"1373_CR44","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2147\/COPD.S108758","volume":"11","author":"GT Ferguson","year":"2016","unstructured":"Ferguson GT, Karpel JP, Clerisme-Beaty E, Gronke L, Voss F, Buhl R. Efficacy and safety of tiotropium\u2009+\u2009olodaterol maintenance treatment in patients with COPD in the TONADO\u00ae and OTEMTO\u00ae studies: a subgroup analysis by age. Int J Chronic Obstr Pulm Dis. 2016;11:2701\u201310.","journal-title":"Int J Chronic Obstr Pulm Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01373-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01373-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01373-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T07:22:06Z","timestamp":1644477726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01373-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01373-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version was revised due to update of graphic abstract.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}